BioDrive, Inc. — FDA Warning Letter, 2026-08-24: Dietary Supplement/Adulterated
Letter issued · posted to fda.gov .
Subject as published: Dietary Supplement/Adulterated
TL;DR
Here's the summary: On August 24, 2026, the FDA's Human Foods Program issued Warning Letter CMS #731846 to BioDrive, Inc. (CEO Cory A. Henderson, New York) regarding the dietary supplement Evolv GLP-1 Biomimetic, which contains Saccharomyces cerevisiae S288C EV-1 Peptide as a declared ingredient. The FDA determined that EV1-Peptide is a new dietary ingredient lacking adequate safety information and presents potential toxicity concerns; BioDrive submitted two new dietary ingredient notifications that FDA objected to on safety grounds, yet proceeded to market the product anyway, rendering it adulterated under the Federal Food, Drug, and Cosmetic Act and prohibited from interstate commerce. The agency requested written response within 15 working days and warned that failure to address violations may result in seizure and injunction.
Argus analysis
# FDA Warning Letter Analysis: BioDrive, Inc.
**Company and Violation**
BioDrive, Inc., a New York-based dietary supplement manufacturer, received a warning letter from the FDA's Human Foods Program on August 24, 2026, regarding its Evolv GLP-1 Biomimetic product. The FDA determined that the supplement is adulterated because it contains Saccharomyces cerevisiae S288C EV-1 Peptide (EV1-Peptide), a new dietary ingredient lacking adequate safety data. The agency found insufficient evidence that EV1-Peptide presents no significant or unreasonable risk of illness or injury to consumers.
**Regulatory Citations and Implications**
The violation centers on 21 CFR § 402(f)(1)(B), which prohibits dietary supplements containing new dietary ingredients without adequate safety information. BioDrive had submitted two new dietary ingredient notifications (NDINs) to FDA, but the agency identified safety concerns, including potential toxicity with serious adverse clinical consequences. Despite these objections, the company proceeded to market the product. Under 21 CFR § 301(a), introducing adulterated supplements into interstate commerce is prohibited. These sections establish that manufacturers bear responsibility for demonstrating ingredient safety before market entry, not after.
**Response Timeline and Industry Watch Points**
BioDrive has 15 working days to submit written corrective actions to the FDA's Office of Enforcement. The company must explain specific steps taken to address violations and provide supporting documentation, or justify any delays. Compliance officers monitoring this case should watch for whether BioDrive initiates a voluntary recall, pursues additional safety studies, or contests the FDA's determination. The agency indicated that failure to adequately respond may trigger seizure or injunction actions. This letter signals the FDA's heightened scrutiny of novel peptide ingredients in GLP-1 adjacent products marketed as dietary supplements.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Dietary supplement Warning Letters typically cite 21 USC 343(r)(6) (structure-function claims), 21 USC 321(g) (drug-vs-supplement classification), or 21 CFR Part 111 (CGMP for supplements). DSHEA-era boundaries are the recurring theme.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER BioDrive, Inc. MARCS-CMS 731846 — August 24, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Product: Dietary Supplements Recipient: Recipient Name Cory A. Henderson Recipient Title CEO BioDrive, Inc. 325 Hudson Street, 4th Floor New York , NY 10013 United States (b)(6), (b)(7)(C) Issuing Office: Human Foods Program United States August 24, 2026 WARNING LETTER CMS #731846 Dear Mr. Henderson: This letter concerns your Evolv GLP-1 Biomimetic dietary supplement. Your product labeling identifies Saccharomyces cerevisiae S288C EV-1 Peptide as a dietary ingredient. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Federal Food, Drug, and Cosmetic Act (the Act). You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov. Adulterated Dietary Supplements The labeling of your Evolv GLP-1 Biomimetic dietary supplement declares “ Saccharomyces cerevisiae S288C EV-1 Peptide” (hereinafter “EV1-Peptide”) as a dietary ingredient. EV1-Peptide is a “dietary ingredient” under section 201(ff)(1)(F) of the Act [21 U.S.C. § 321(ff)(1)(F)]. EV1-Peptide is also a “new dietary ingredient” under section 413(d) of the Act [21 U.S.C. § 350b(d)] because, to the best of FDA’s knowledge, there is no information demonstrating that EV1-Peptide was marketed as a dietary ingredient in the United States before October 15, 1994. A dietary supplement is adulterated under section 402(f)(1)(B) of the Act [21 U.S.C. § 342(f)(1)(B)] if it contains a new dietary ingredient for which there is inadequate information to provide a reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury. Based on our evaluation of the relevant safety evidence, there is inadequate information to provide reasonable assurance that EV1-Peptide does not present a significant or unreasonable risk of illness or injury. Therefore, your Evolv GLP-1 Biomimetic containing the EV1-Peptide is adulterated under section 402(f)(1)(B) of the Act. The introduction of the adulterated dietary supplement into interstate commerce is prohibited under section 301(a) of the Act [21 U.S.C. § 331(a)]. Moreover, available information on the use of EV1-Peptide in products raises serious safety concerns. You submitted two new dietary ingredient notifications (NDINs) to FDA in which we determined there was inadequate information to conclude that a dietary supplement containing EV1-Peptide would reasonably be expected to be safe. Specifically, FDA identified safety concerns due to potential toxicity, which raised concerns for adverse clinical consequences. You proceeded to market Evolv GLP-1 Biomimetic despite FDA’s objections due to safety concerns. Conclusion This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for invest…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to BioDrive, Inc.?
- FDA issued the letter (MARCS-CMS 731846) on 2026-08-24 and posted it publicly on fda.gov on 2026-09-22.
- Is the FDA warning letter to BioDrive, Inc. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/biodrive-inc-731846-08242026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Dietary supplement warning letter?
- Dietary supplement Warning Letters typically cite 21 USC 343(r)(6) (structure-function claims), 21 USC 321(g) (drug-vs-supplement classification), or 21 CFR Part 111 (CGMP for supplements). DSHEA-era boundaries are the recurring theme.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). BioDrive, Inc. — FDA Warning Letter, 2026-08-24: Dietary Supplement/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-biodrive-inc-2026-08-24-dietary-supplement
"BioDrive, Inc. — FDA Warning Letter, 2026-08-24: Dietary Supplement/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-biodrive-inc-2026-08-24-dietary-supplement.
Argus HQ Research. "BioDrive, Inc. — FDA Warning Letter, 2026-08-24: Dietary Supplement/Adulterated." Digital Empire Holdings LLC. Accessed September 25, 2026. https://argushq.ai/fda/warning-letter/fda-wl-biodrive-inc-2026-08-24-dietary-supplement.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_biodrive_inc_2026_08_24_dietary_supplement_2026,
title = {BioDrive, Inc. — FDA Warning Letter, 2026-08-24: Dietary Supplement/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-biodrive-inc-2026-08-24-dietary-supplement},
note = {Accessed: September 25, 2026}
}